10-Q: Akero Therapeutics Q2 2025: Losses Mount Amid Phase 3 Push

Akero Therapeutics reports increased net losses in Q2 2025 as it advances its lead MASH drug candidate, EFX, through a global Phase 3 clinical program.

Summary

• Net loss for the three months ended June 30, 2025, increased to $70.5 million, up from $56.0 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $141.2 million, compared to $109.3 million for the six months ended June 30, 2024.
• Accumulated deficit reached $967.4 million as of June 30, 2025.
• Cash, cash equivalents, short-term, and long-term marketable securities totaled $1,086.2 million as of June 30, 2025, providing an expected cash runway into 2028.
• Research and development expenses increased by $13.9 million (25%) to $69.3 million for the three months ended June 30, 2025, primarily due to increased CMO and CRO expenses for the ongoing Phase 3 SYNCHRONY program.
• The lead product candidate, efruxifermin (EFX), is an analog of FGF21, being developed for metabolic dysfunction-associated steatohepatitis (MASH).
• The global Phase 3 SYNCHRONY program, comprised of Outcomes, Histology, and Real-World trials, aims to enroll approximately 3,500 patients to support marketing approval applications for pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4) due to MASH.
• Preliminary topline Week 96 results from the Phase 2b SYMMETRY trial showed 39% of patients treated with 50mg EFX experienced reversal of cirrhosis with no worsening of MASH, compared to 15% for placebo (p=0.009).
• Preliminary topline Week 96 results from the Phase 2b HARMONY trial demonstrated 75% (p<0.001) for 50mg EFX and 46% (p=0.07) for 28mg EFX achieved 1-stage improvement in fibrosis with no worsening of MASH, compared to 24% for placebo.
• EFX has been generally well-tolerated across clinical trials, with most adverse events being mild or moderate, and low discontinuation rates.
• Enrollment for the double-blind portion of the SYNCHRONY Real-World trial was completed in January 2025, with results expected in the first half of 2026.
• The company raised $402.5 million gross proceeds from a follow-on public offering and $10.6 million from an ATM offering in January 2025.
• An ongoing class-action lawsuit, Klobus v. Akero Therapeutics, Inc., alleging misstatements regarding the Phase 2b SYMMETRY study, was dismissed without prejudice on May 5, 2025, but a second amended complaint was filed on May 26, 2025, and a motion to dismiss was filed on June 16, 2025.

Sentiment

Score: 7

Explanation: The company is progressing its lead candidate, EFX, through pivotal Phase 3 trials with promising Phase 2b data. While losses are increasing, this is expected for a clinical-stage biotech with significant R&D spend. The strong cash position provides a long runway, mitigating immediate funding concerns. The ongoing lawsuit is a negative, but its impact is currently undetermined.

Positives

• Strong cash, cash equivalents, and marketable securities balance of $1,086.2 million as of June 30, 2025.
• Extended cash runway, expected to fund operating expenses and capital expenditure requirements into 2028.
• Positive preliminary topline Week 96 results from the Phase 2b SYMMETRY trial, showing statistically significant cirrhosis reversal (39% for 50mg EFX vs. 15% placebo, p=0.009).
• Positive preliminary topline Week 96 results from the Phase 2b HARMONY trial, demonstrating significant fibrosis improvement (75% for 50mg EFX vs. 24% placebo, p<0.001).
• EFX has been generally well-tolerated across clinical trials with low treatment-emergent adverse event discontinuation rates.
• Completion of enrollment for the double-blind portion of the Phase 3 SYNCHRONY Real-World trial.
• Successful capital raise of over $400 million in January 2025, strengthening the financial position.
• EFX has received Breakthrough Therapy designation and Fast Track designation for the treatment of MASH.

Negatives

• Increased net loss to $70.5 million for Q2 2025, a 26% increase compared to $56.0 million in Q2 2024.
• Accumulated deficit has grown to $967.4 million as of June 30, 2025.
• No revenue generated to date, and profitability is not expected for the foreseeable future.
• Significant increase in research and development expenses, up 25% to $69.3 million in Q2 2025, driven by advanced clinical trial and manufacturing activities.
• Heavy dependence on the success of EFX, which is currently the only product candidate in clinical stages of development.
• An ongoing class-action lawsuit related to alleged misstatements regarding the Phase 2b SYMMETRY study, despite an initial dismissal, has been refiled and is proceeding.

Risks

• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with MASH, significant competition for recruiting such patients in clinical trials, and restrictions on patients and investigators related to outbreaks of infectious diseases or public health crises.
• Substantial competition exists from multinational pharmaceutical companies, specialized biotechnology companies, and research institutions, which may result in others discovering, developing, or commercializing products before or more successfully.
• Failures or delays in the commencement or completion of, or ambiguous or negative results from planned clinical trials could result in increased costs and delay, prevent, or limit the ability to generate revenue.
• Clinical development is uncertain, and clinical trials for EFX and any future product candidates may experience delays, adversely affecting regulatory approvals or commercialization.
• Reliance on third parties to conduct clinical trials poses risks if they do not successfully carry out contractual duties, meet expected deadlines, or comply with regulatory requirements.
• The manufacture of product candidates is complex, and difficulties in production or failure to meet rigorously enforced regulatory standards could delay or stop supply or impact cost structure.
• Heavy dependence on the success of EFX, the only product candidate, makes the business vulnerable to any problems encountered in its development and commercialization.
• Failure to develop and successfully commercialize other product candidates would harm business and future prospects.
• Developing EFX, and potentially future product candidates, in combination with other therapies exposes the company to additional risks.
• Inability to discover, develop, receive regulatory approval for, and commercialize EFX and any future product candidates would impair business expansion and strategic objectives.
• Significant payments may be required under the license agreement for EFX.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable, and inability to obtain approval would substantially harm the business.
• Even if regulatory approvals are obtained, harmful side effects after approval could lead to regulatory revocation or costly product liability claims.
• Relationships with customers and third-party payors are subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which, if violated, could expose the company to criminal sanctions, civil penalties, and reputational harm.
• Significant losses have been incurred since inception, and losses are expected for the foreseeable future.
• Limited operating history, no revenue to date, and may never become profitable.
• Additional capital will be required to finance operations, which may not be available on acceptable terms, potentially preventing completion of development and commercialization.
• Operating activities may be restricted by covenants related to the term loan obligation, which may be required to be repaid in an event of default.
• The level of indebtedness and debt service obligations could adversely affect financial condition and make it more difficult to fund operations.
• Even if commercialized, products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties to sell and market products could hinder commercialization.
• Product candidates may not achieve adequate market acceptance among physicians, patients, third-party payors, and others in the medical community.
• Significant costs and time are expended operating as a public company, with management devoting substantial time to compliance initiatives and corporate governance practices.
• Failure to maintain an effective system of internal controls over financial reporting could lead to inaccurate financial reporting or fraud.
• Information technology systems or data compromises, including those enhanced by AI, could result in regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Use and generation of hazardous materials may expose the company to material liability.
• Unfavorable global economic conditions, including geopolitical tensions (e.g., Middle East conflict impacting clinical sites in India, Israel, Turkey), inflation, and interest rates, could adversely affect business.
• Reliance on single-source unaffiliated third-party suppliers for raw materials and services, including China-based suppliers, poses supply chain risks.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations.
• The market price of stock may be volatile, and the company could incur significant costs from class action securities litigation.
• Anti-takeover provisions under organizational documents and Delaware law could delay or prevent a change of control.
• Changes in tax laws could adversely affect business and financial condition.
• Inability to utilize a significant portion of net operating loss carryforwards and research and development tax credit carryforwards due to ownership changes.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances EFX through later-stage clinical development and pursues additional product candidates. Significant commercialization expenses are anticipated if marketing approval is obtained. Existing cash, cash equivalents, and marketable securities of $1,086.2 million are projected to fund operations into 2028. Additional funding will be required to complete EFX's clinical development, commercialization (if approved), and to pursue new in-licenses or acquisitions. Results from the Phase 3 SYNCHRONY Real-World trial are expected in the first half of 2026. Final commercial supply agreements with manufacturers are expected to be in place before the SYNCHRONY Histology study readout.

Management Comments

• We believe EFX has the potential, if approved, to be an important medicine for treating MASH.
• We also believe EFX may be able to be used in combination with other therapies for potentially greater effect in certain subpopulations, particularly among the substantial proportion of patients with both MASH and type 2 diabetes who are expected to be treated with GLP-1 therapeutics to manage their diabetes and/or obesity.
• We expect to continue to incur significant expenses and operating losses for the foreseeable future.
• We expect that our research and development expenses will increase substantially in the near term and in the future, due to planned manufacturing and clinical development activities necessary to support the ongoing development of EFX.
• We believe this [existing cash, cash equivalents, short-term and long-term marketable securities of $1,086.2 million] will be sufficient to fund our current operating plan into 2028.
• We intend to vigorously defend against the lawsuit.

Industry Context

Akero Therapeutics operates in the highly competitive biotechnology industry, focusing on metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The market for MASH treatments is evolving, with new approvals like Rezdiffra™ and other investigational drugs potentially impacting patient enrollment in clinical trials. The company's lead candidate, EFX, an FGF21 analog, aims to address this high unmet medical need. The industry faces increasing legislative and regulatory scrutiny regarding drug pricing, as evidenced by the Inflation Reduction Act (IRA) and the recently signed One Big Beautiful Bill Act (OBBBA), which introduce changes to tax laws and drug price negotiation. Geopolitical tensions, such as the conflict in the Middle East, are noted as potential risks to clinical trial sites in affected regions. The increasing adoption and regulatory focus on artificial intelligence also present new risks and challenges for the industry.

Comparison to Industry Standards

• EFX's Phase 2b SYMMETRY trial demonstrated 39% cirrhosis reversal with no MASH worsening for the 50mg EFX group, compared to 15% for placebo, indicating strong efficacy within its own trial context.
• The HARMONY Phase 2b trial showed 75% fibrosis improvement for 50mg EFX and 46% for 28mg EFX, compared to 24% for placebo, suggesting a robust response rate for its target indication.
• The company acknowledges substantial competition from major pharmaceutical and biotechnology companies such as AstraZeneca, Eli Lilly, GSK, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, and Madrigal Pharmaceuticals (developer of Rezdiffra™), but does not provide direct comparative data against their specific products or clinical results.
• The company notes that cross-trial comparisons of results are not robust comparative analyses and may suggest misleading similarities or differences due to variations in study protocols, conditions, and patient populations.

Corporate Governance

Legal Proceedings

• A class action lawsuit, Klobus v. Akero Therapeutics, Inc., was filed on April 26, 2024, in the U.S. District Court for the Northern District of California against the company and three officers.
• The suit alleges misstatements and omissions regarding the Phase 2b SYMMETRY study, on behalf of stockholders who purchased common stock between September 13, 2022, and October 9, 2023.
• The court initially dismissed the suit in its entirety without prejudice on May 5, 2025.
• Lead Plaintiffs filed a second amended complaint on May 26, 2025, and Defendants moved to dismiss it on June 16, 2025.
• Oral arguments on the motion to dismiss the second amended complaint were heard on August 5, 2025.
• The company intends to vigorously defend against the lawsuit, and the probability or amount of potential related costs cannot be determined due to the early stage of the matter.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and stock price volatility, but also potential long-term value appreciation if EFX achieves commercial success.
• Employees are subject to a competitive hiring environment, with increased headcount expected and stock-based compensation as a significant component of their remuneration.
• Future patients with MASH could benefit from EFX as a new treatment option if it receives regulatory approval.
• Contract manufacturing organizations (CMOs) and contract research organizations (CROs) will continue to be key partners, with increased R&D expenses indicating ongoing reliance and payments for clinical trial and manufacturing activities.
• Creditors, specifically Hercules Capital, Inc., are impacted by the company's adherence to loan covenants and repayment obligations for the outstanding term loan.

Next Steps

• Continue the global Phase 3 SYNCHRONY program, including Outcomes, Histology, and Real-World trials.
• Report results from the SYNCHRONY Real-World trial in the first half of 2026.
• Negotiate and enter into final commercial supply agreements with Boehringer Ingelheim and Vetter prior to the readout of the Phase 3 SYNCHRONY Histology study.
• Seek regulatory approval for EFX if clinical development is successful.
• Potentially develop EFX in combination with other therapies.
• Discover, develop, and commercialize a portfolio of other product candidates.
• Explore strategic collaborations for the development or acquisition of new product candidates.
• Incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution if products are approved.
• Incur expenses in connection with the in-licensing or acquisition of additional product candidates.
• Continue to attract and retain qualified scientific, technical, and business personnel.
• Monitor and upgrade internal controls as necessary.

Key Dates

Recommendation

Akero Therapeutics is a clinical-stage biotechnology company with a single lead product candidate, EFX, in late-stage development for MASH. While the Phase 2b results for EFX are promising and the company has a strong cash position to fund operations into 2028, the company continues to incur significant losses as expected for its stage of development. The ongoing class-action lawsuit introduces an element of uncertainty and potential future costs. Given the high-risk, high-reward nature of clinical-stage biotech and the current stage of EFX development, a 'Hold' recommendation is appropriate for investors who already have exposure, awaiting further clarity from the Phase 3 SYNCHRONY trial results (expected H1 2026 for Real-World) and the resolution of the legal proceedings. For new investors, the risk profile remains high, but the potential upside from EFX approval is substantial.

Keywords

Biotechnology, MASH, NASH, MASLD, NAFLD, Efruxifermin, EFX, FGF21, Clinical Trials, Phase 3, SYNCHRONY, Liver Disease, Fibrosis, Cirrhosis, Drug Development, Pharmaceutical, Biotech, Healthcare, Therapeutics